Galactomannan Testing in Mucormycosis

Diagnostic Considerations

When imaging shows invasive fungal disease but galactomannan is negative in both serum and bronchoalveolar lavage, clinicians should have high suspicion for mucormycosis rather than aspergillosis, as recommended by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM) with a Strength of Recommendation B 1, 2, 3
The ESCMID/ECMM guidelines specifically recommend considering mucormycosis when galactomannan tests are negative but radiology is positive for invasive fungal disease (Strength of Recommendation B) 1, 2, 4
Mucormycosis requires liposomal amphotericin B (5-10 mg/kg/day), NOT voriconazole, which is ineffective against Mucorales, according to treatment guidelines 5
Urgent surgical debridement is essential in addition to antifungal therapy for mucormycosis treatment 5
If both galactomannan AND beta-D-glucan are negative, this pattern further increases likelihood of mucormycosis, as Mucorales also lack beta-D-glucan in their cell walls 2, 7
Obtain tissue diagnosis urgently, as direct microscopy, culture, and histopathology remain the gold standard for mucormycosis diagnosis with a Strength of Recommendation A 1, 2, 8

The American College of Clinical Microbiology does not have specific guidelines for mucormycosis treatment, however, the Infectious Diseases Society of America recommends liposomal amphotericin B as the primary treatment option 5
Don't assume negative galactomannan rules out invasive fungal infection—it may indicate mucormycosis, which has higher mortality than aspergillosis if treatment is delayed, as stated by the ESCMID 1, 5
Don't rely solely on serology—tissue diagnosis with histopathology showing characteristic hyphal morphology is essential for definitive diagnosis of mucormycosis 1, 2, 6